REBECCA REED: Open Payments
NPI 1417349572 · WEST COLUMBIA, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,149 in 99 payments from 28 companies in 2025. Trend: 2023 $927 · 2024 $2,290 · 2025 $2,149
Food & beverage: $2,068Education: $80
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 20 | $390 |
| GlaxoSmithKline, LLC. | 16 | $266 |
| GENZYME CORPORATION | 8 | $231 |
| Regeneron Healthcare Solutions, Inc. | 3 | $151 |
| United Therapeutics Corporation | 5 | $141 |
| Dexcom, Inc. | 4 | $96 |
| Verona Pharma, Inc. | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $64 |
| ANI Pharmaceuticals, Inc. | 3 | $63 |
Products named: DUPIXENT, FASENRA, NUCALA, Tyvaso, TRELEGY ELLIPTA, Dexcom G6 Transmitter, TEZSPIRE, AIRSUPRA.
Industry payments across SC — which companies pay providers there.
